TACSTD2 and cancer: (2) Therapeutic targets exhibiting sharp upward growth trends(most noticeably in 2022) in co-occurring frequency with substancesinclude dendritic cells, cancer-associated fibroblasts (CAFs), tumor-associatedmacrophages (TAMs), STING, gasdermins, CDC20, TROP2, LILRB1, TBK1,PKM2, protein kinase B (PKB), NIMA-related kinase 2 (NEK2), and ARG1.